Efficient Production of Bioactive Insulin from Human Epidermal Keratinocytes and Tissue-Engineered Skin Substitutes: Implications for Treatment of Diabetes

PEDRO LEI, ADEBIMPE OGUNADE, KEITH L. KIRKWOOD, SUZANNE G. LAYCHOCK, and STELIOS T. ANDREADIS

ABSTRACT

Despite many years of research, daily insulin injections remain the gold standard for diabetes treatment. Gene therapy may provide an alternative strategy by imparting the ability to secrete insulin from an ectopic site. The epidermis is a self-renewing tissue that is easily accessible and can provide large numbers of autologous cells to generate insulin-secreting skin substitutes. Here we used a recombinant retrovirus to modify human epidermal keratinocytes with a gene encoding for human proinsulin containing the furin recognition sequences at the A-C and B-C junctions. Keratinocytes were able to process proinsulin and secrete active insulin that promoted glucose uptake. Primary epidermal cells produced higher amounts of insulin than cell lines, suggesting that insulin secretion may depend on the physiological state of the producer cells. Modified cells maintained the ability to stratify into 3-dimensional skin equivalents that expressed insulin at the basal and suprabasal layers. Modifications at the furin recognition sites did not improve proinsulin processing, but a single amino acid substitution in the proinsulin B chain enhanced C-peptide secretion from cultured cells and bioengineered skin substitutes 10- and 28-fold, respectively. These results suggest that gene-modified bioengineered skin may provide an alternative means of insulin delivery for treatment of diabetes.

INTRODUCTION

Diabetes mellitus is a group of diseases characterized by an absolute or relative insulin deficiency and poor glucose control (hyperglycemia) in the blood. In type 1 diabetes, also known as insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes mellitus, there is an absolute lack of insulin due to the progressive loss of pancreatic β-cells in the islets of Langerhans. Destruction of pancreatic islet β-cells is governed in part by hereditary and environmental factors such as viruses, toxins, dietary proteins, and stress. In type 2 diabetes, insulin is present, but the signal for proper glucose uptake is lost because of nutritional or genetic factors. Despite intense research efforts, daily insulin injections remain the gold standard for diabetes treatment, although the discomfort to patients may be significant. On the other hand, islet transplantation suffers from scarcity of donors, the need for long-term immunosuppression, and short-term survival of transplanted cells because of recurrence of anti-islet cell autoimmunity. Therefore, engineering alternative routes of physiologic insulin delivery is a major goal of diabetes research.

Because type 1 diabetes results from lack of insulin production in the pancreas, it is reasonable to assume that secretion of insulin from ectopic sites might overcome the insulin deficit. Several cell types have been used to produce

1Bioengineering Laboratory, Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Amherst, New York; 2Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, Michigan; 3Department of Pharmacology and Toxicology, University of Buffalo, The State University of New York, Amherst, New York.
surrogate β-cells using gene therapy approaches. Neuroendocrine cells have been proposed as candidates for glucose-responsive insulin secretion because, like β-cells, they have active constitutive and regulated secretory pathways and express proprotein convertases PC2 and PC1/3 that are required for proinsulin processing.6 A major drawback of neuroendocrine cells is that other hormones that are co-secreted with insulin may have adverse side effects.7 The common ancestry of liver and pancreas—both arise from the gut endoderm during embryogenesis—and the biochemical functions of hepatocytes in glucose homeostasis and ketogenesis have spurred interest in redirecting the fate of cells in the adult liver to function as insulin-secreting pancreatic β-cells.8,9 Transfer of genes that regulate insulin expression such as Pdx1, neurogenin differentiation-1 (NeuroD1) and betacellulin (a member of the epidermal growth factor receptor family) afforded β-cell phenotype to liver cells and reversed streptozotocin (STZ)-induced diabetes in vivo.10-12 However, adverse effects have also been observed, with expression of Pdx1 for 4 weeks resulting in death of the C57BL/6 mice, possibly due to co-expression of trypsin, a digestive enzyme that is also regulated by Pdx1.12 Other surrogate targets that have been proposed for insulin delivery include intestinal cells13 and dermal fibroblasts.14,15

In contrast to tissues such as those in the pituitary gland or liver, the skin is easily accessible, facilitating isolation of epidermal cells from the patient. Epidermal keratinocytes can be easily expanded in culture, genetically modified, and used to prepare 3-dimensional (3D) skin equivalents. Use of autologous cells obviates the need for immuno-isolation devices or immunosuppressive drugs during transplantation of engineered tissues. Accessibility also allows for the removal of transplanted tissue if adverse effects occur. Finally, genetically modified epidermal cells have been shown to secrete large amounts of proteins that reach the systemic circulation via capillaries (molecular weight < 16 kDa) or via the lymphatic return system (molecular weight > 16 kDa).16-20 These advantages make skin an ideal organ for ectopic gene delivery.

Recent studies have provided strong evidence of the feasibility and effectiveness of cutaneous gene therapy. The first study demonstrated partial correction of hemophilia A after grafting factor VIII–deficient mice with skin from factor VIII–expressing transgenic animals.21 The second study employed retroviral gene transfer of the leptin gene into human keratinocytes to examine the effectiveness of gene therapy for obesity, diabetes, and infertility associated with leptin deficiency. Tissue-engineered skin with genetically modified keratinocytes was grafted onto transgenic obese (ob/ob) mice, resulting in significant weight reduction and reversal of the obese phenotype.22 Skin grafts constituting less than 10% of the body surface area were sufficient for the correction of leptin deficiency. Finally, a recent study indicated that epidermal cells can efficiently secrete large antibody molecules (150 kDa), which can then enter the systemic circulation.23 Collectively, these studies suggest that cutaneous gene therapy may be an efficient clinical modality for the treatment of systemic disorders.

In this study, we modified human epidermal keratinocytes with a gene encoding for wild-type (hppI1) or furin-cleavable (hppI4) proinsulin. We showed that keratinocytes can process proinsulin with furin cleavage sites into mature insulin. Insulin-secreting keratinocytes retained the ability to develop into a stratified epithelium with basal, suprabasal, granular, and cornified layers and to secrete biologically active insulin. To further improve insulin production, we introduced several modifications at the furin cleavage sites and the B chain of proinsulin. Additional arginine residues in the furin recognition sites did not improve processing of proinsulin. However, a single point mutation in the B chain enhanced insulin production significantly, reaching levels as high as 140 pmol/cm² of bioengineered skin tissue per day. These data suggest that genetically engineered skin may provide an alternative means of delivering insulin for treatment of diabetes.

**MATERIALS AND METHODS**

**Retrovirus production and cell culture**

The retroviral plasmid BMNIG was kindly provided by Dr. Gary Nolan (Stanford University, CA). From 5' to 3', this vector contains the 5' viral long terminal repeat (LTR), the retroviral packaging sequence (Ψ), a multiple cloning site (MCS), and the internal ribosomal entry site (IRES) sequence, followed by the green fluorescent protein (GFP) and the 3' viral LTR. Wild-type proinsulin (hppI1) and furin-cleavable proinsulin (hppI4) genes were kindly provided by Dr. Dochartney (University of Aberdeen, UK). For cloning, hppI1 and hppI4 were digested using SalI and NotI and ligated into the XhoI and NotI sites of the multiple cloning site of pBMNIG (Fig. 1A). To produce amphotropic retrovirus, human kidney epithelial cell–derived packaging cells (Phoenix-ampho; provided by Dr. G. Nolan) were plated in tissue culture flasks (2.5 × 10⁵ cells/cm²) and incubated overnight. The next day, retroviral plasmids (1 µg per 2.5 × 10⁵ cells) and FuGENE 6 (Roche, Indianapolis, IN) were mixed (1 µg:3 µL) in 100 µL of Dulbecco’s modified Eagle medium (DMEM; Gibco BRL, Grand Island, NY) without serum or antibiotics. The mixture was incubated at room temperature for 15 to 45 min and then added to the culture medium of packaging cells. The next day (18-24 h later), the culture medium was replenished, and retrovirus was harvested twice at 24 and 48 h after medium exchange.

Phoenix-ampho cells were cultured in DMEM supplemented with 10% heat-inactivated bovine serum (Clontech, Logan, UT) and 100 U of penicillin and 100 µg/mL streptomycin (P/S; Gibco BRL), at 37°C with 10% carbon dioxide (CO₂). Mouse pre-adipocytes (3T3-L1) were kindly provided by Dr. Kyongbum Lee (Tufts University, Medford, MA) and cultured in DMEM plus 1% P/S plus 10% bovine serum (Gibco BRL) at 37°C and 10% CO₂ within 15 passages. To induce differentiation into adipocytes, pre-
adipocytes were cultured to confluence, and the medium was replaced with induction medium-1 (IM1) for 3 to 6 days, followed by IM2 for 3 days and maintenance medium for another 4 to 6 days before adipocytes were used in glucose uptake assays. Maintenance medium was composed of DMEM plus 1% P/S plus 10% fetal bovine serum (FBS; Gibco BRL); IM2 was the same as maintenance medium supplemented with 1 mg/mL insulin; IM1 was the same as IM2 supplemented with 1 μM dexamethasone and 0.5 mM 1-isobutyl-3-methylxanthine (Aldrich, St Louis, MO). Human keratinocytes were isolated from neonatal foreskins following the protocol established by Green et al. and expanded on feeder layers of 3T3-J2 mouse fibroblasts (ATCC, Manassas, VA) as described previously. Keratinocytes used in experiments were maintained in keratinocyte serum–free medium (keratinocyte SFM; Gibco BRL) within 1 to 4 passages. Two human epidermal cell lines (HaCaT cells, kindly provided by Dr. Satrajit Sinha; State University of New York at Buffalo, Buffalo, NY, and A431 epidermoid carcinoma cells, ATCC) were cultured in DMEM supplemented with 1% P/S and 10% FBS at 37°C with 10% CO2.

**Transduction protocol**

Non-tissue culture-treated 24-well plates were incubated overnight at 4°C with 400 μL of recombinant fibronectin (rFN) fragment CH296 (Takara Mirus Bio Corporation, Madison, WI) in deionized water (10 μg/mL). Retrovirus (250–400 μL/well) was added in rFN-coated wells and incubated at 37°C in the presence of 10% CO2 for 6 to 7 h (transduction with rFN-immobilized retrovirus). At the end of virus incubation, human epidermal keratinocytes were added at 12,500 cells/cm² in 500 μL of keratinocyte SFM. The next day (~24 h later), a fresh stock of retrovirus without polybrene was added to the cells (transduction on rFN). After 2 h of incubation, retrovirus was removed from all wells and replaced with fresh keratinocyte SFM. The medium was replenished every 2 to 3 days until the cells reached 80% to 90% confluence, at which time they were processed for flow cytometry.

**Flow cytometry**

Keratinocytes were washed once with 0.48 mM ethylenediaminetetraacetic acid (EDTA, Sigma, St. Louis, MO) in phosphate buffered saline (PBS) and detached from the surface using trypsin-EDTA (Gibco BRL). The trypsin was inactivated with culture medium containing 10% FBS, cells were centrifuged (5 min; 800 g) and resuspended in PBS with 1.0 mg/mL of propidium iodide (PI; Molecular Probes, Grand Island, NY) for 15 min at 4°C. Only viable cells (PI–) were used to determine the fraction of transduced (GFP+) cells.

**Measurement of proinsulin and C-peptide**

When modified cells reached confluence, they were replenished with fresh keratinocyte SFM. Subsequently, conditioned medium was harvested daily and stored at −75°C until use. The amount of proinsulin was quantified using an enzyme-linked immunosorbent assay (ELISA) kit for human proinsulin (Human Total Proinsulin ELISA Kit; Linco Research, Inc., St. Charles, MO), and the amount of C-peptide was measured using an ELISA kit for human C-peptide (Human C-Peptide ELISA Kit; Linco Research, Inc.), according to the manufacturer’s instructions.

**Glucose uptake assay**

Mouse adipocytes were serum starved for 1.5 to 2.5 h, followed by stimulation with conditioned medium from
keratinocytes for 15 min at 5% CO₂ and 37°C. Next, cells were incubated with 14C-deoxyglucose (0.05 μCi, final concentration 60 mM) in Krebs-Ringer-phosphate 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (10 mM HEPES, pH 7.4; 131.2 mM sodium chloride; 4.7 mM potassium chloride; 1.2 mM magnesium sulfate; 2.5 mM calcium chloride (CaCl₂); 2.5 mM sodium dihydrogen phosphate) for 5 min at 5% CO₂ and 37°C. At the end of incubation, cells were placed immediately on ice to inhibit uptake. After 4 washes with ice-cold PBS, cells were lysed with lysis buffer (200 μL of 2% deoxycholate and 10 μL of 10 N sodium hydroxide) for 1 h at 37°C, and radioactivity was measured using a scintillation counter.

**Generation of hppI4/+furin + HaCaT cells**

HaCaT cells were transduced using a retrovirus encoding for hppI4 as described above. Once the cells became confluent, they were sorted for GFP expression using fluorescence activated cell sorting. After sorting, the insulin-expressing hppI4 + cells were transfected with pcDNA3.1-furin (generously provided by Dr. James Binley, The Scripps Research Institute, La Jolla, CA) using Lipofectamine reagent (Gibco BRL). Briefly, pcDNA3.1-furin (2 μg per 2.5 × 10⁵ cells) and lipofectamine were mixed in a 1:1 ratio in 500 μL of DMEM without serum or antibiotics. The mixture was incubated at room temperature for 15 to 45 min. At the end of incubation, the mixture was added to hppI4 + cells in DMEM without serum or antibiotics for 6 h. The medium was replaced, and 2 days later, transfected cells were passaged at clonal density and grown in selection medium containing a lower concentration of G418 (0.4 mg/mL).

**Polymerase chain reaction**

Polymerase chain reaction (PCR) was performed using the iCycler (BioRad Laboratories, Hercules, CA). The reaction was carried out in a volume of 50 μL containing 20 or 200 ng of plasmid deoxyribonucleic acid (DNA), 2 μM of each primer (Sigma Genosys, Woodlands, TX), 200 μM of each deoxyribonucleotide triphosphate (dNTP), and 2.5 units of polymerase (PfuUltra HF DNA polymerase; Stratagene, La Jolla, CA). The annealing temperature and magnesium chloride (MgCl₂) concentrations for each reaction were optimized to maximize product formation and minimize primer-dimer formation (Table 1). The specificity of the PCR products was confirmed using electrophoresis on 0.7% agarose gels.

**Site-directed mutagenesis of proinsulin B chain**

A 3-step PCR was used to create the histidine (H) to aspartic acid (D) mutation at the tenth amino acid on the B-chain of proinsulin (hppI4HD). First, to create the point mutation on the sense DNA, the plasmid pBMN(hppI4)IG was subjected to PCR using primers 2 and 3 as forward and reverse primers, respectively (Table 1). Next, to create mutation on the antisense DNA, a second PCR was performed using primers 1 and 4 (Table 1). Finally, the 2 PCR products were subjected to 8 cycles of primerless PCR, followed by 25 cycles of PCR with primers 1 and 2. Briefly a 50-μL reaction mixture containing 10 μL of each primer, 200 μM of each dNTP, high-fidelity polymerase, and the corresponding buffer was prepared. After 8 cycles of PCR at an annealing temperature of 65°C and 1.5 mM MgCl₂, primers were added to a final concentration

---

**Table 1. Polymerase Chain Reaction Conditions and Primers**

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer Sequence</th>
<th>Magnesium Chloride Concentration (mM)</th>
<th>Annealing Temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5'-CCCCACGCCCTCAAAGTACGC-3'</td>
<td>2.5</td>
<td>55</td>
</tr>
<tr>
<td>2</td>
<td>5'-AAAGACGGCAATATGTGGGAAAAT-3'</td>
<td>1.5</td>
<td>50</td>
</tr>
<tr>
<td>3</td>
<td>5'-CACCTGTCGGCTCAGACCTGTTGGAAGCTC-3'</td>
<td>1.5</td>
<td>50</td>
</tr>
<tr>
<td>4</td>
<td>5'-GAGAGCGTCCACCCAGGTCAAGCGAGAGGCT-3'</td>
<td>2.5</td>
<td>55</td>
</tr>
<tr>
<td>5</td>
<td>5'-TTCTACACACCCAGCGCCGGACGAGGAGGAC-3'</td>
<td>2.5</td>
<td>71</td>
</tr>
<tr>
<td>6</td>
<td>5'-GTCTCTCGTCCTCCGGCGACGAGGCTTGTTGGTGTTAGA-3'</td>
<td>2.5</td>
<td>71</td>
</tr>
<tr>
<td>7</td>
<td>5'-TTGCGGCTTGAGGGTGCTGTCGCGCGAGAGCATT-3'</td>
<td>2.5</td>
<td>71</td>
</tr>
<tr>
<td>8</td>
<td>5'-AATTGACGCCATCCGCCGCGAGAGCATTCCAGGCCA-3'</td>
<td>2.5</td>
<td>71</td>
</tr>
<tr>
<td>9</td>
<td>5'-TTCTACACACCCAGCGCCGGACGAGGAGGAC-3'</td>
<td>2.5</td>
<td>66</td>
</tr>
<tr>
<td>10</td>
<td>5'-GTCTCTCGTCCTCCGGCGACGAGGCTTGTTGGTGTTAGA-3'</td>
<td>2.5</td>
<td>66</td>
</tr>
<tr>
<td>11</td>
<td>5'-TTGCGGCTTGAGGGTGCTGTCGCGCGAGAGCATTCCAGGCCA-3'</td>
<td>2.5</td>
<td>68–75</td>
</tr>
<tr>
<td>12</td>
<td>5'-CACAATGCGGCCTCCGCGGCGCTCGAGACTCCCTTCCAGGCCA-3'</td>
<td>2.5</td>
<td>71</td>
</tr>
<tr>
<td>13</td>
<td>5'-AAGGAGCGACGGCTCAGTGGAGAGGAGGAC-3'</td>
<td>2.5</td>
<td>68–75</td>
</tr>
<tr>
<td>14</td>
<td>5'-AAGGGGGATATCGTGACCACCTATGGCTGGGC-3'</td>
<td>2.5</td>
<td>68–75</td>
</tr>
</tbody>
</table>
of 2 μM each, and PCR was allowed to run for 25 additional cycles. Subsequently, the PCR product was subcloned into pCR2.1TOPO vector (Invitrogen, Grand Island, NY) according to the manufacturers’ instructions, and the resulting plasmid was named TOPO-hppl4-HD. To generate retroviral vector encoding for hppl4-HD, the insert hppl4-HD from TOPO-hppl4-HD was digested using BamHI and ligated into the MCS of pQCXIP (P = puromycin resistant gene; Clontech, Palo Alto, CA) and pQCXIG (G = GFP; described below). The resulting plasmids were called pQC(hppl4-HD)IP and pQC(hppl4-HD)IG, respectively (Fig. 1A).

The plasmid pQCXIG was derived from pQCXIX (Clontech). Briefly, the gfp gene sequence from pBMNIG was amplified by PCR using primers that added MluI and EcoRV sites to the 5’ and 3’ ends of the gene, respectively (primers 13 and 14; Table 1). The reaction product was digested using MluI and EcoRV and subsequently ligated into the second MCS of pQCXIX. Retroviral plasmids pQC(hpl11/4)IP and pQC(hpl11/4)IG were generated by digesting hpl11/4 from pBMN(hpl11/4)IG with BamHI and ligating into the MCS of pQCXIP and pQCXIG, respectively (Fig. 1A). All plasmids were sequenced before use.

Site directed mutagenesis at furin consensus sequences

Introduction of an extra 1 or 2 arginines (R) at the furin cleavages sites was achieved using the QuikChangeII Site-Directed Mutagenesis Kit (Stratagene), according to the manufacturer’s instructions (Table 2). First, to insert an additional R in the furin consensus sequence at the B-C junction, PCR was performed using TOPO-hppl4-HD as template and primers 5 and 6 (Table 1). The resulting vector, TOPO-hppl4-HD-BR1, was used as a PCR template, along with primers 7 and 8 to add one R to the furin consensus sequence at the A-C junction. The resulting product, TOPO-hppl4-HD-BR1AR1, was used as a PCR template along with primers 9 and 10 to introduce an additional R in the furin consensus sequence at the B-C junction, yielding construct TOPO-hppl4-HD-BR2AR1. Finally, insulin containing 2 extra R’s in each furin cleavage site was created using TOPO-hppl4-HD-BR2AR1 as a PCR template and primers 11 and 12. After generating all the mutants in the TOPO vector, the mutated proinsulin sequences were subsequently digested using BamHI and ligated into the MCS of pQCXIP or pQCXIG. All plasmids were sequenced before use.

Preparation of skin equivalents

Skin equivalents were prepared as previously described. Briefly, square pieces of acellular dermis (1 cm²) were placed, basement membrane side up, into 6-well tissue-culture dishes. A freshly prepared suspension of keratinocytes from 3T3-J2 feeder layers (5×10⁶ cells/mL) in keratinocyte seeding medium (described below) was added onto the papillary side of the dermis (~100 μL, or enough to cover the surface) or on collagen-coated polycarbonate membranes (Transwell, Corning Costar, Cambridge, MA). Approximately 1.5 h after cell seeding, the skin equivalents were submerged in keratinocyte seeding medium for 24 h. Keratinocyte seeding medium was a 3:1 mixture of DMEM and Ham’s F-12 medium (Gibco BRL) supplemented with 1% FBS, 1% P/S, 10⁻¹⁰ M chola toxin (Vibrio cholerae, type Inaba 569 B; Calbiochem, La Jolla, CA), 0.4 μg/mL hydrocortisone (Calbiochem), and 5 μg/mL recombinant insulin (Sigma). After 24 h, keratinocyte seeding medium was removed, and the skin equivalents were submerged for an additional 48 h in a keratinocyte priming medium. Keratinocyte priming medium was composed of keratinocyte seeding medium supplemented with 24 μM bovine serum albumin, 1.0 mM L-serine, 10 μM L-carnitine, and a cocktail of fatty acids (25 μM oleic acid, 15 μM linoleic acid, 7 μM arachidonic acid, and 25 μM palmitic acid (all Sigma)). After 48 h in priming medium, skin equivalents were placed on stainless steel screens, raised to the air–liquid interface, and cultured with an air–liquid interface medium composed of serum-free keratinocyte priming medium supplemented with 1 ng/mL epidermal growth factor (Collaborative Biomedical Products, Bedford, MA). Skin equivalents were cultured at the air–liquid interface for 7 days, with air–liquid interface medium replaced every 3 days, or daily for C-peptide/proinsulin measurements.

Histology and immunohistochemistry

For histology, skin equivalents were embedded in paraffin and stained with hematoxylin and eosin, as previously described. For fluorescence imaging, skin equivalents were fixed in 4% paraformaldehyde in PBS for 4 h at 4°C, followed by treatment with 0.1 M ice-cold glycine for 1 h and overnight incubation in 0.6 M sucrose solution at 4°C. Tissues were embedded in O.C.T. (Sakura Finetek, Torrance, CA), frozen on dry ice, and kept at −75°C until use. To visualize GFP, the sections were washed twice with PBS and mounted with an aqueous mounting medium (Gel/Mount; Biomed, Foster City, CA). Fluorescent images of the sections were obtained using an inverted fluorescence microscope (Nikon Diaphot, Garden City, NY).

<table>
<thead>
<tr>
<th>Name</th>
<th>H to D Mutation at Position B10</th>
<th>Furin Consensus Sequence</th>
<th>A-C junction</th>
<th>B-C junction</th>
</tr>
</thead>
<tbody>
<tr>
<td>hpl14</td>
<td>No</td>
<td>RRKR</td>
<td>RRKR</td>
<td></td>
</tr>
<tr>
<td>hpl14-HD</td>
<td>Yes</td>
<td>RRKR</td>
<td>RRKR</td>
<td></td>
</tr>
<tr>
<td>hpl14-HD-BR1AR1</td>
<td>Yes</td>
<td>RRKR</td>
<td>RRKR</td>
<td></td>
</tr>
<tr>
<td>hpl14-HD-BR2AR1</td>
<td>Yes</td>
<td>RRKR</td>
<td>RRKR</td>
<td></td>
</tr>
<tr>
<td>hpl14-HD-BR2AR2</td>
<td>Yes</td>
<td>RRKR</td>
<td>RRKR</td>
<td></td>
</tr>
</tbody>
</table>
Statistical analysis

Statistical analysis of the data was performed using the Tukey’s honestly significant difference test ($\alpha = 0.05$).

RESULTS

Efficient transduction of primary human keratinocytes using proinsulin-encoding retrovirus

We transduced primary human keratinocytes with retrovirus encoding for the proinsulin gene that was modified to contain furin cleavage sites in place of the regular convertase sites.24 Many cell types, including keratinocytes, which do not express the proprotein convertases PC1/3 and PC2 that are required for proinsulin processing, ubiquitously express the protease furin.31 Proinsulin with (hppI4) or without (hppI1) furin cleavage sites was cloned into the retroviral vector pBMNIG under the viral LTR, followed by the IRES and GFP (Fig. 1A). IRES permits expression of hppI1/4 and GFP from the same promoter, and because IRES is partially inactivated, GFP is expressed to a lesser extent than proinsulin. As a result, all cells that express GFP should express even higher amounts of hppI1/4.

Keratinocytes were transduced on rFN using a protocol that yielded high efficiencies of retroviral gene transfer to primary human keratinocyte stem cells.29 Specifically, keratinocytes were plated on rFN-coated plates preloaded with retrovirus and the next day exposed to the virus for another 2 h. Polybrene was not used in either step, because previous studies have showed that polybrene decreased gene transfer by inhibiting binding of retrovirus to the heparin-binding domain of rFN.32,33 This protocol yielded approximately 60% transduced GFP $^+$ cells, as determined using flow cytometry (Fig. 1B).

Primary human keratinocytes express high levels of proinsulin and insulin

The amount of proinsulin secreted from the hppI1- and hppI4-transduced cells was 10 and 0.2 pmol proinsulin/10$^6$ cells per day, respectively, as determined using ELISA. As expected, no proinsulin was observed in non-transduced cells or cells transduced with the control BMNIG retrovirus (Fig. 2A).

Because exogenous insulin in the culture medium is required to maintain keratinocyte cell proliferation,34,35 we quantified the amount of insulin secreted from transduced cells by measuring the amount of C-peptide using ELISA. The antibody that was used in this assay recognized free C-peptide as well as C-peptide in intact proinsulin. The amount of C-peptide from hppI1 cells was 8 to 10 pmol/10$^6$ cells per day, confirming the proinsulin data (Fig. 2B). On the other hand, hppI4 cells secreted 1.3 pmol/10$^6$ cells per day of C-peptide but only 0.2 pmol/10$^6$ cells per day of proinsulin (Fig. 2A), suggesting that proinsulin was processed into mature insulin successfully.

Bioengineered skin equivalents from transduced keratinocytes produce insulin

Although hppI4 keratinocytes secreted insulin in conventional cell culture, it was not certain whether these cells retained the ability to stratify into insulin-producing 3D skin
substitutes. To address this point, we engineered skin equivalents by seeding hppI4 keratinocytes on decellularized dermis and raising them to the air–liquid interface. We found that hppI4 cells developed into a fully stratified epithelium with basal, suprabasal, granular, and cornified layers, similar to control, non-transduced cells (Fig. 3A, B; hematoxylin and eosin). Fluorescence microscopy of cryosections revealed GFP expression throughout the epidermis, with the highest levels detected in the suprabasal layers (Fig. 3C), in accordance with our previous observations. Similar results were observed with hppI1 tissues (data not shown). HppI1 tissues secreted C-peptide at a rate of 10 pmol/cm² tissue per day for the first 4 days, but the rate declined at later times, approaching a plateau by day 7. On the other hand, hppI4 tissues secreted C-peptide at a constant rate of 2.5 pmol/cm² tissue per day over 7 days in culture at the air–liquid interface (Fig. 3D).

**Upregulation of furin enhances insulin production**

In 2D and 3D cell culture systems, C-peptide production from hppI4 cells was consistently lower than that from hppI1 cells, despite similar transduction efficiencies. Because production of insulin from hppI4 cells requires the action of furin, we hypothesized that expression of furin may limit proinsulin processing. To address this hypothesis, we transduced HaCaT cells, an epidermal cell line, with hppI4 encoding retrovirus and sorted GFP⁺ cells using flow cytometry. After expansion, hppI4 cells were transfected with a plasmid encoding for the furin gene and selected in G418-containing medium for 2 weeks. The amount of C-peptide that hppI4⁺/furin⁺ cells secreted was three times greater than that of control hppI4⁺ cells (Fig. 4), suggesting that the proteolytic activity of furin may limit processing of proinsulin in epidermal keratinocytes.

---

**FIG. 3.** Proinsulin and insulin production from modified tissue-engineered skin equivalents. Human keratinocytes were non-transduced (NT) or transduced with hppI1 or hppI4 encoding retrovirus. Skin equivalents were generated by seeding keratinocytes onto the papillary side of decellularized dermis and raising them to the air–liquid interface for 7 days to allow complete stratification. Paraffin sections of skin equivalents from (A) NT or (B) hppI4 keratinocytes were stained with hematoxylin and eosin (40x). (C) Frozen sections of hppI4 tissues after 7 days at the air–liquid interface were used to evaluate gene expression (GFP, green; 40x). The dotted line denotes the basement membrane that separates the epidermis from the dermis. (D) Conditioned medium was harvested from skin equivalents daily after they were raised to the air–liquid interface. C-peptide in conditioned medium was detected using enzyme-linked immunosorbent assay and reported as cumulative amount of C-peptide levels normalized to the area of the tissue (per cm²). All values are the mean ± standard deviation of triplicate samples in a representative experiment (n = 3). B, basal; SP, suprabasal; G, granular; SC, cornified (stratum corneum) cell layers; and D: dermis. Color images available online at www.liebertpub.com/ten.
An amino acid substitution increases insulin production by epidermal keratinocytes significantly

Previous studies have reported that a point mutation at the tenth amino acid of the proinsulin B-chain increased binding to insulin receptor and the activity of insulin significantly.\(^\text{36,37}\) Others showed that furin is a relatively slow enzyme and that altering the furin consensus sequence increased the cleavage efficiency of the human immunodeficiency virus (HIV) envelope precursor gp160.\(^\text{38}\) Based on these results, we attempted to increase the amount of insulin from hppI4 keratinocytes by taking a 2-prong approach. First, we mutated the tenth amino acid in the proinsulin B-chain from histidine to aspartic acid (HB10D) and used the resulting vector as a template for site-directed mutagenesis to introduce additional arginines in the furin recognition sequences at the A-C and B-C junctions (Table 2). The resulting proinsulin genes were then cloned into a self-inactivating retroviral vector, pQCXIP (Fig. 1A). HaCaT cells and A431 squamous carcinoma cells were transduced with recombinant retrovirus encoding for the altered proinsulin constructs and selected with puromycin.

The HB10D substitution resulted in 6- or 10-fold increase in C-peptide production from HaCaT or A431 cells, respectively (Fig. 5). On the other hand, changes in the furin recognition sequence did not increase insulin production. In contrast, an extra arginine at the A-C and B-C furin cleavage sites (BR1AR1) resulted in a moderate reduction (~25%) in C-peptide secretion from A431 cells. The decrease was more pronounced (~50%) when 2 additional arginines were inserted in the furin consensus sequence (BR2AR2). HaCaT cells yielded a significantly lower level of C-peptide than A431 cells and remained unaffected by changes in the furin cleavage sites.

To examine whether altered proinsulin constructs had similar effects on primary cells, we cloned the mutated proinsulin genes into the pQCXIG retroviral plasmid (Fig. 1A) that encodes for GFP instead of puromycin, thus allowing quantitation of transduced cells using flow cytometry. Keratinocytes transduced with the pQC(hppI4)IG retroviral vector secreted higher levels of C-peptide (4.6 pmol/10^6 cells per day) than those transduced with the pBMN(hppI4)IG vector (1.3 pmol/10^6 cells per day), possibly reflecting differences in strength of the 2 promoters (viral LTR vs. cytomegalovirus). Most important, the H to D substitution in the proinsulin level from modified cells was low, suggesting that the mutations did not adversely affect proinsulin processing in keratinocytes.

**FIG. 4.** Overexpression of furin increases proinsulin processing. HaCaT cells were transduced with retrovirus encoding for hppI4. Once the cells reached confluence, hppI4 + cells were sorted using fluorescence activated cell sorting. The hppI4 + cells were transfected with pcDNA3.1-furin using lipofectamine and selected with Geneticin (G418) for 2 weeks. The amount of C-peptide from hppI4 + or hppI4 + /furin + was measured using enzyme-linked immunosorbent assay. All values are the mean ± standard deviation of triplicate samples in a representative experiment (n = 3).

**FIG. 5.** A single amino acid mutation in the B-chain of proinsulin (HB10D) enhanced C-peptide secretion significantly. HaCaT and A431 epidermal cell lines were each transduced with retroviruses encoding for hppI4, hppI4-HD, hppI4-HD-BR1AR1, or hppI4-HD-BR2AR2. After 2 weeks of antibiotic selection in puromycin, C-peptide secretion from modified cells was measured using enzyme-linked immunosorbent assay. All values are the mean ± standard deviation of triplicate samples in a representative experiment (n = 3). The asterisks (*) denote p < 0.05 between the indicated samples.
To evaluate insulin secretion from stratified tissues, keratinocytes were modified with hppI4 or hppI4-HD retrovirus and used to prepare bioengineered skin. We found that hppI4 and hppI4-HD tissues secreted C-peptide at a rate of 5 and 140 pmol/cm² tissue per day, respectively. These data show that the H to D mutation increased secretion from 3D tissues to a larger extent than cells in culture (28- vs. 10-fold), suggesting that stratification may have increased the ability of keratinocytes to express and process proinsulin significantly (Fig. 6B).

Insulin secreted by keratinocytes is biologically active

To determine whether insulin produced by keratinocytes was active, we measured glucose uptake by mouse adipocytes (3T3-L1) in response to conditioned medium from genetically modified keratinocytes. In accordance with the ELISA data, treatment of 3T3-L1 cells with conditioned medium from hppI4 and hppI4-HD cells enhanced glucose uptake 4- and 33-fold, respectively, over conditioned medium from unmodified cells (Fig. 7). These data indicate that wild-type and mutated insulin produced from epidermal keratinocytes remained biologically active. The specific activity (glucose uptake per ng of C-peptide) of conditioned medium from hppI4 cells was similar to that of hppI4-HD cells, suggesting that increased glucose uptake was due to increased production of insulin (hppI4-HD) rather than superior binding to the insulin receptor.
its subsequent processing into insulin. In particular, the C-peptide plays an important role in folding of proinsulin and the structure of insulin. Recent studies have showed that C-peptide has a role in insulin secretion from A431 cells but had no effect on secretion from HaCaT cells or primary keratinocytes, indicating that other mechanism(s) may also be at work. In addition to expression level, the enzymatic activity of furin might be low because of lack of co-factors or suboptimal furin recognition sequence in the proinsulin gene. The activity of furin was shown to require calcium, it was possible that treatment with higher calcium concentrations might improve insulin production. However, treatment of keratinocytes with up to 2 mM CaCl₂ yielded a modest 50% increase in C-peptide secretion (data not shown). A recent study showed that introduction of 2 arginines at the C-peptide cleavage sites (RRKR → RRRRRR, RRRRRR → RRRKKR, and RRRKKR → RRRK) enhanced furin activity, resulting in elevated levels of production of the HIV envelope protein gp120. In contrast, we found that the same mutations decreased insulin secretion from A431 cells but had no effect on secretion from HaCaT cells or primary keratinocytes, suggesting that the action of furin may depend on the physiological state of the producer cell. Alternatively, the furin recognition sequence may affect the structure of insulin. Recent studies have showed that C-peptide plays an important role in folding of proinsulin and its subsequent processing into insulin. In particular, mutations in the highly conserved acidic residues, EAED, at the N terminus of the C-peptide resulted in protein aggregation during refolding. To engineer the furin cleavage site at the B-C junction, the acidic residue at the N terminus of C-peptide was converted to a basic residue (E → R). This substitution may have altered the protein folding pattern, resulting in a less stable form of proinsulin, and consequently reduced the level of secreted insulin. 

In addition to varying the furin consensus sequence, we attempted to improve insulin production by a single amino acid substitution at the tenth position of the proinsulin B-chain. Previous studies have showed that this single-point mutation enhanced insulin stability and production level 10- to 100-fold compared with wild-type insulin. The H to D mutation increased insulin secretion from 2D keratinocyte cultures and 3D skin substitutes 10- and 28-fold, respectively. The higher increase observed in stratified tissues, in accordance with our previous data, as well as the data of others, showed that differentiated suprabasal keratinocytes expressed higher levels of the transgene than basal cells. Higher transgene expression in suprabasal layers may reflect a higher metabolic state of differentiated keratinocytes or higher expression of furin. No matter what the mechanism may be, this result is important, because the majority of keratinocytes in stratified tissues are situated in the suprabasal layers, suggesting that gene-modified bioengineered skin may be efficient in secreting insulin in vivo.

The daily rate of C-peptide production by hppI4 and hppI4-HD keratinocytes was 4.6 and 45.5 pmol/10⁶ cells per day, corresponding to 27 and 270 ng of insulin/10⁶ cells per day, respectively. These levels are significantly higher than the levels of insulin production by other cell types such as HepG2 (3.6 ng/10⁶ cells per day), NIH-3T3 (3.1 ng/10⁶ cells per day), human fibroblasts (3.9 ng/10⁶ cells per day), and human myoblasts (13.2 ng/10⁶ cells per day) transduced with insulin-encoding retrovirus. Modified keratinocytes retained the ability to stratify, and the resulting bioengineered skin secreted C-peptide at a rate of 140 pmol/cm² tissue per day. The reported C-peptide concentration in human serum after islet transplantation was approximately 1.0 ng/mL. The volume of serum is approximately 40% of the blood volume or 2 L (assuming 5 L of blood in a 70-kg adult), yielding a total of 2,000 ng or 625 pmol of C-peptide. Based on the daily rate of C-peptide secretion by skin substitutes (140 pmol/cm² of tissue per day), the stability of C-peptide in serum (half-life = 174 h), and the clearance of C-peptide in blood (half-life = 30-60 min), we calculated that the area of transplanted skin tissue required to produce insulin at a molar amount equal to that of transplanted islets is between 75 cm² (8.5 cm × 8.5 cm) and 150 cm² (12 cm × 12 cm). The calculated area of skin grafts is only 0.37% to 0.75% of the total skin surface area of the average adult (~2 m²), suggesting that bioengineered skin may provide an efficient vehicle for insulin release to substitute or complement insulin injections. Continuous delivery of basal levels of insulin provided by genetically modified cells has been shown to have beneficial effects on glucose levels. In this manner, genetically modified skin substitutes may be used as “bioreactors” to provide continuous delivery of basal levels of insulin.
of insulin and maintain glucose control under fasting conditions. Depending upon the functionality of the pancreatic islet \(\beta\)-cells, low doses of exogenous insulin may still be required to maintain normoglycemia after meals. Therefore, the combination of a continuous source of insulin with lower doses of insulin therapy may reduce the number of injections and at the same time provide tight glycemic control, ultimately reducing long-term complications. Finally, molecular switches can be designed and incorporated into our retroviral or lentiviral vectors to provide glucose-controlled secretion of insulin, as demonstrated previously.\(^{56–58}\) These systems are currently under development in our laboratory.

**ACKNOWLEDGMENTS**

This work was supported by National Institutes of Health Grants R01 DK068699-01 (S.T.A.), R01 DK068673-01 (K.L.K.), and DK068700-02 (S.G.L.).

**REFERENCES**

55. Riu, E., Mas, A., Ferre, T., Pujol, A., Gros, L., Otaegui, P., Montoliu, L. and Bosch, F. Counteraction of type 1 diabetic


Address reprint requests to:
Stelios T. Andreadis
Bioengineering Laboratory
908 Furnas Hall
Department of Chemical and Biological Engineering
University at Buffalo, The State University of New York
Amherst, NY 14260
E-mail: sandread@eng.buffalo.edu
This article has been cited by: